Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind placebo-controlled study of VP4896 (leuprolide) for mild-to-moderate Alzheimer's disease
2005-003214-15Phase 3Completed
- Sponsor
- Voyager Therapeutics
- Start
- Sep 2005
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing VP4896 (leuprolide) with Placebo (2 arms). Primary endpoint: Primary safety and efficacy endpoints. Started Sep 2005; status: completed.
02
Drugs
leuprolide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2005-003214-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003214-15.